New agents for the management of resistant metastatic breast cancer

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Introduction: Metastatic breast cancer (MBC) is an incurable disease and treatment is directed towards symptom palliation and survival prolongation. Treatment selection in patients is based on tumor biology, age, comorbidities, performance status, tumor burden, and prior treatment history. Areas covered: This present review summarizes the recent treatment strategies in the management of MBC, highlighting regimens after first-line therapy. Topics discussed include new strategies for endocrine therapy, anti-HER2 therapy, and promising strategies for the management of triple negative breast cancer. Expert opinion: MBC is a heterogeneous entity and despite recent advances, there is significant room for improvement of treatment beyond first-line therapies. Combination regimens that can maximize clinical efficacy while minimizing toxicities are required. Current investigation approaches in advanced stages of clinical development include immunoconjugates, immune checkpoint blockade, novel cyclin-dependent-kinase inhibitors, and PARP inhibitors for MBC associated with germline BRCA mutations. We recommend that every patient with MBC should be evaluated for clinical trial options.

Original languageEnglish (US)
Pages (from-to)1815-1831
Number of pages17
JournalExpert Opinion on Pharmacotherapy
Volume18
Issue number17
DOIs
StatePublished - Nov 22 2017

Fingerprint

Breast Neoplasms
Therapeutics
Immunoconjugates
Triple Negative Breast Neoplasms
Cyclin-Dependent Kinases
Germ-Line Mutation
Expert Testimony
Tumor Burden
Patient Selection
Comorbidity
History
Clinical Trials
Survival
Neoplasms

Keywords

  • advanced
  • anti-HER2 therapy
  • Breast cancer
  • chemotherapy
  • endocrine therapy
  • metastatic

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

New agents for the management of resistant metastatic breast cancer. / Anampa Mesias, Jesus D.; Sparano, Joseph A.

In: Expert Opinion on Pharmacotherapy, Vol. 18, No. 17, 22.11.2017, p. 1815-1831.

Research output: Contribution to journalReview article

@article{40cb196e32c74fd1933dbeea13b98915,
title = "New agents for the management of resistant metastatic breast cancer",
abstract = "Introduction: Metastatic breast cancer (MBC) is an incurable disease and treatment is directed towards symptom palliation and survival prolongation. Treatment selection in patients is based on tumor biology, age, comorbidities, performance status, tumor burden, and prior treatment history. Areas covered: This present review summarizes the recent treatment strategies in the management of MBC, highlighting regimens after first-line therapy. Topics discussed include new strategies for endocrine therapy, anti-HER2 therapy, and promising strategies for the management of triple negative breast cancer. Expert opinion: MBC is a heterogeneous entity and despite recent advances, there is significant room for improvement of treatment beyond first-line therapies. Combination regimens that can maximize clinical efficacy while minimizing toxicities are required. Current investigation approaches in advanced stages of clinical development include immunoconjugates, immune checkpoint blockade, novel cyclin-dependent-kinase inhibitors, and PARP inhibitors for MBC associated with germline BRCA mutations. We recommend that every patient with MBC should be evaluated for clinical trial options.",
keywords = "advanced, anti-HER2 therapy, Breast cancer, chemotherapy, endocrine therapy, metastatic",
author = "{Anampa Mesias}, {Jesus D.} and Sparano, {Joseph A.}",
year = "2017",
month = "11",
day = "22",
doi = "10.1080/14656566.2017.1409206",
language = "English (US)",
volume = "18",
pages = "1815--1831",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "17",

}

TY - JOUR

T1 - New agents for the management of resistant metastatic breast cancer

AU - Anampa Mesias, Jesus D.

AU - Sparano, Joseph A.

PY - 2017/11/22

Y1 - 2017/11/22

N2 - Introduction: Metastatic breast cancer (MBC) is an incurable disease and treatment is directed towards symptom palliation and survival prolongation. Treatment selection in patients is based on tumor biology, age, comorbidities, performance status, tumor burden, and prior treatment history. Areas covered: This present review summarizes the recent treatment strategies in the management of MBC, highlighting regimens after first-line therapy. Topics discussed include new strategies for endocrine therapy, anti-HER2 therapy, and promising strategies for the management of triple negative breast cancer. Expert opinion: MBC is a heterogeneous entity and despite recent advances, there is significant room for improvement of treatment beyond first-line therapies. Combination regimens that can maximize clinical efficacy while minimizing toxicities are required. Current investigation approaches in advanced stages of clinical development include immunoconjugates, immune checkpoint blockade, novel cyclin-dependent-kinase inhibitors, and PARP inhibitors for MBC associated with germline BRCA mutations. We recommend that every patient with MBC should be evaluated for clinical trial options.

AB - Introduction: Metastatic breast cancer (MBC) is an incurable disease and treatment is directed towards symptom palliation and survival prolongation. Treatment selection in patients is based on tumor biology, age, comorbidities, performance status, tumor burden, and prior treatment history. Areas covered: This present review summarizes the recent treatment strategies in the management of MBC, highlighting regimens after first-line therapy. Topics discussed include new strategies for endocrine therapy, anti-HER2 therapy, and promising strategies for the management of triple negative breast cancer. Expert opinion: MBC is a heterogeneous entity and despite recent advances, there is significant room for improvement of treatment beyond first-line therapies. Combination regimens that can maximize clinical efficacy while minimizing toxicities are required. Current investigation approaches in advanced stages of clinical development include immunoconjugates, immune checkpoint blockade, novel cyclin-dependent-kinase inhibitors, and PARP inhibitors for MBC associated with germline BRCA mutations. We recommend that every patient with MBC should be evaluated for clinical trial options.

KW - advanced

KW - anti-HER2 therapy

KW - Breast cancer

KW - chemotherapy

KW - endocrine therapy

KW - metastatic

UR - http://www.scopus.com/inward/record.url?scp=85036558866&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85036558866&partnerID=8YFLogxK

U2 - 10.1080/14656566.2017.1409206

DO - 10.1080/14656566.2017.1409206

M3 - Review article

VL - 18

SP - 1815

EP - 1831

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 17

ER -